RT期刊文章SR电子T1疾病和治疗反应在儿童复发髓少突细胞糖蛋白抗体(MOG-Ab)相关疾病(S51.008)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S51.008 VO 90 15 A1雅艾尔补充Hacohen A1 Wong团队A1拥有基督教莱希A1 Maciej Jurynczyk A1 Sukhvir赖特A1 Bahadi首页r Konuskan A1安妮丽莎Poulat A1 Helene Maurey A1伊万杰琳沃斯默A1谢丽尔海明威A1 Eva玛丽亚Hennes A1玛丽亚雷特A1奥尔加Ciccarelli A1 Banu Anlar A1 Rogier Hintzen A1罗曼Marignier A1杰奎琳宫A1马提亚鲍曼A1凯文Rostesy A1 Rinze f . Neuteboom A1库玛Deiva A1明Lim年2018 UL //www.ez-admanager.com/content/90/15_Supplement/S51.008.abstract AB目的:描述的临床表型,治疗反应和复发MOG-Ab-associated患儿疾病的结果。背景:MOG-Ab一直确认的脱髓鞘疾病的成人和儿童。当前的治疗策略主要是center-specific和没有正式evaluatedDesign /治疗方法:前瞻性收集人口、临床和放射学数据来自8个国家的欧盟儿科脱髓鞘疾病财团。患者治疗根据当地协议。年复发率(ARR)和扩展残疾状态量表(eds)评分和治疗疾病修饰药物(诊断)计算。结果:102名儿童被识别;他们最初的诊断视神经节neuromyelitis谱系障碍(43.1%)、急性播散性脑脊髓炎其次是视神经炎(19.6%)、多相播散性脑脊髓炎(19.6%),复发性视神经炎(17.6%)。总共有464脱髓鞘事件队列中被报道。没有病人的人口统计和脱髓鞘表型的差异在发病和治疗病人治疗,但是治疗病人有更多的复发(p = 0.0094)和更高的比未经处理的eds (p < 0.0001)。诊断有52名儿童(51%):28(53.8%)与一个DMD患者治疗,17例(32.7%)有两个,7例(13.5%)有三个或更多的连续监测诊断。在所有治疗复发的患者共有127复发治疗报告队列。任何更改在加勒比海盗和eds观察pre -和β干扰素post-initiation glatiramer醋酸(n = 11)。加勒比海盗与咪唑硫嘌呤从1.84减少到1.0 (n = 20, p = 0.0004);1.79到0.52,霉酚酸酯(n = 15, p = 0.0028); 2.12 to 0.67 with Rituximab(n=9, p=0.0008), although the EDSS remained unchanged. An improvement in both ARR (2.16 to 0.51, p<0.0001) and EDSS (2.2 to 1.2, p=0.013) was observed in patients treated with regular intravenous immunoglobulins (n=12).Conclusions: DMDs commonly used to treat MS patients were not associated with clinical improvement in children with MOG-Ab-associated disease, whilst azathioprine, mycophenolate mofetil, Rituximab, and particularly IVIG, were associated with a reduction in relapse frequency.Disclosure: Dr. Hacohen has nothing to disclose. Dr. Yuyi has nothing to disclose. Dr. Lechner has nothing to disclose. Dr. Jurynczyk has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Konuskan has nothing to disclose. Dr. Poulat has nothing to disclose. Dr. Maurey has nothing to disclose. Dr. Wassmer has nothing to disclose. Dr. Hemingway has nothing to disclose. Dr. Hennes has nothing to disclose. Dr. Leite has nothing to disclose. Dr. Ciccarelli has nothing to disclose. Dr. Anlar has nothing to disclose. Dr. Hintzen has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Palace has nothing to disclose. Dr. Baumann has nothing to disclose. Dr. Rostasy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with served as a consultant for PARADIGMS study. Dr. Neuteboom has nothing to disclose. Dr. Deiva has nothing to disclose. Dr. Lim has nothing to disclose.